MoonLake Immunotherapeutics (MLTX) stock gains as Rothschild & Co Redburn upgrades the company to Buy, citing FDA nod for lead asset sonelokimab. Read more here.
MoonLake upgraded at Rothschild & Co Redburn (MLTX:NASDAQ)
MoonLake Immunotherapeutics (MLTX) stock gains as Rothschild & Co Redburn upgrades the company to Buy, citing FDA nod for lead asset sonelokimab. Read more here.